While the physiologic significance of our findings is limited by the use of in vitro models, these should stimulate the CF scientific community to further address the potential gains of adding HGF to current CFTR modulator combinational therapies, namely by using currently available in vivo and ex vivo (patient-derived tissues and organoids) models. The gene discussed is HGF; the disease is cystic fibrosis.